Drug Trial Radar · NCT05315258
Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma
Last checked: Nov 20, 2026Latest source record: Jul 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
850
Planned (sponsor's estimate)
Start
Jul 25, 2022
Primary completion
Dec 30, 2026
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- University of OxfordAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Immunocore Ltd
- First posted
- Apr 7, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are trying to find ways to improve the management of people with intermediate or high risk resected cutaneous melanoma or with primary uveal melanoma. This research study is investigating using a new blood test to decide when to give a drug called tebentafusp. Tebentafusp has been used in clinical trials in patients with advanced cutaneous and uveal melanoma. This study is designed to determine if tebentafusp can help patients with cutaneous or uveal melanoma live longer.
Conditions
- Melanoma (Skin)
- Melanoma, Uveal
Interventions
TebentafuspDrug
Tebentafusp supplied as concentrate for solution for infusion and diluted prior to administration. 0.2 mg/mL drug product will be provided as a sterile, refrigerated solution in glass vials.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Estimate the rate of molecular response (MR) to tebentafusp in each of 2 cohorts A. Cutaneous melanoma with MRD B. Uveal melanoma with MRDTime frame: ctDNA taken at baseline until end of treatment (maximum of 6 months)
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Cambridge University Hospitals NHS Foundation Trust (Screening only)
Cambridge, United Kingdom
The Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom
The Clatterbridge Cancer Centre
Liverpool, United Kingdom
University College London Hospital
London, United Kingdom
The Christie Hospital
Manchester, United Kingdom
Mount Vernon Cancer Centre
Middlesex, United Kingdom
Newcastle upon Tyne Hospitals NHS Foundation Trust
Newcastle, United Kingdom
Churchill Hospital, Oxford University Hospitals NHS Trust
Oxford, United Kingdom
Sheffield Teaching Hospitals NHS Foundation Trust (Screening only)
Sheffield, United Kingdom
University Hospital Southampton NHS Foundation Trust
Southampton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.